Given the tumor suppressive nature of CDK10 in breast cancer, HCC, BTC and gastric cancer, targeting CDK10 via pan-CDK inhibitors may have limited the therapeutic response. This evidence concerns the gene CDK10 and hepatocellular carcinoma.